BMS, Compugen Pursue Multiple Checkpoint Inhibitions In Antibody Collaboration

Bristol-Myers Squibb is teaming up with Compugen to test the latter’s investigational antibody that targets a new checkpoint, PVRIG, in combination with its own antibody Opdivo. Combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT, is also on the cards for the future.

The Israeli drug discovery and development company Compugen Inc. has joined forces with Bristol-Myers Squibb Co. to evaluate the safety and tolerability of Compugen’s COM701 in combination with BMS’s PD-1 inhibitor Opdivo (nivolumab) in patients with advanced solid tumors.

COM701 is an antibody targeting a new checkpoint discovered by Compugen, PVRIG (PVR Related Immunoglobulin Domain Containing) in T-cells. PVRL2...